Prix Shanghai Bio-heart Biological Technology Co Ltd (02185.HK)

Shanghai Bio-Heart Biological Technology Co., Ltd. engages in the research and development of interventional cardiovascular device therapies. The company is headquartered in Shanghai, Shanghai and currently employs 70 full-time employees. The company went IPO on 2021-12-23. The firm's main businesses are the development and production of interventional cardiovascular devices. The firm's main products comprise fully bioresorbable scaffolds (BRS) and renal denervation (RDN). The firm's products are mainly used to meet medical needs for the treatment of coronary, peripheral artery disease and hypertension. The firm's products are used in addressing the unmet medical needs of Chinese patients for the treatment of coronary artery diseases and the unmet medical needs of patients for the treatment of uncontrolled hypertension. The firm mainly conducts its businesses in the domestic market and overseas markets.